Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Drops By 9.5%

Health Catalyst, Inc. (NASDAQ:HCAT) saw a significant decline in short interest in July. As of July 31st, there was short interest totalling 2,200,000 shares, a decline of 9.5% from the July 15th total of 2,430,000 shares. Based on an average daily trading volume, of 571,300 shares, the short-interest ratio is currently 3.9 days.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the sale, the chief operating officer now directly owns 150,006 shares in the company, valued at approximately $928,537.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 13,035 shares of company stock valued at $81,396. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Valmark Advisers Inc. purchased a new stake in Health Catalyst during the fourth quarter worth about $1,204,000. Primecap Management Co. CA boosted its stake in shares of Health Catalyst by 26.7% during the 4th quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock worth $13,145,000 after acquiring an additional 299,139 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in Health Catalyst in the 1st quarter valued at approximately $8,780,000. ClariVest Asset Management LLC raised its holdings in Health Catalyst by 303.9% during the first quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock worth $2,126,000 after purchasing an additional 212,425 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Health Catalyst by 38.3% in the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after purchasing an additional 200,494 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Down 0.2 %

NASDAQ:HCAT traded down $0.01 during mid-day trading on Friday, reaching $6.76. 556,798 shares of the stock were exchanged, compared to its average volume of 598,123. The stock has a market capitalization of $398.78 million, a P/E ratio of -3.65 and a beta of 1.32. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $12.45. The company has a 50 day simple moving average of $6.62 and a 200-day simple moving average of $7.19.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The business had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, research analysts predict that Health Catalyst will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Piper Sandler decreased their price objective on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a report on Thursday, June 6th. Wells Fargo & Company lowered their target price on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, August 9th. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price objective on shares of Health Catalyst in a report on Tuesday, May 21st. Finally, Evercore ISI decreased their target price on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.